Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228195 · ClinicalTrials.gov registry record · Phase 4
SGLT2i Therapy in Islet Transplantation (SIT)
A Phase 4 study, sponsored by University of Minnesota.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT07228195: Clinical Trial Phase 4 study, sponsored by University of Minnesota.
NCT07228195 is a Phase 4 study that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228195, a Phase 4 study, has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Primary Outcome
the primary comparison is between three treatment arms (control, empagliflozin 10 mg, and empagliflozin 25 mg) at 3 months on treatment
Interventions
- DRUG Empagliflozin 25 MG Oral Tablet
- DRUG Empagliflozin 10 MG Oral Tablet [Jardiance]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
What is known before NCT07228195 opens enrollment
NCT07228195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Empagliflozin 25 MG Oral Tablet is the first listed.
NCT07228195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07228195 about?
NCT07228195 is a clinical study titled "SGLT2i Therapy in Islet Transplantation (SIT)". This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
What is the current status of trial NCT07228195?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-07-15. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07228195?
The interventions under investigation include: Empagliflozin 25 MG Oral Tablet (DRUG), Empagliflozin 10 MG Oral Tablet [Jardiance] (DRUG).
Who is sponsoring clinical trial NCT07228195?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07228195's enrollment target sits among peer trials
40 1397th of 2000 higher than 533 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI